NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
Masimo Corporation MASI recently announced the publication of the results of a prospective study in the Sri Lanka Journal of Child Health, demonstrating the efficacy of using Masimo Signal Extraction ...
Furthering its move into the neonatal space, this morning non-invasive patient monitoring device and sensor maker Masimo announced that it landed FDA clearance for its acoustic respiration sensor, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results